Proceedings: Chemotherapy of adenocarcinoma of the kidney.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000477:Alkylating Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011372:Progestins / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000728:Androgens; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D011372:Progestins; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D008727:Methotrexate